Curve Dental vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud dental practice management software offering an all-in-one platform for single offices and growing dental groups. Layton UT; founded 2004; one of the earliest true cloud dental PMS alternatives to legacy Dentrix and Eaglesoft;
About
Curve Dental is a Layton, Utah-based cloud-based dental practice management software company that offers an all-in-one platform combining scheduling, clinical charting, digital imaging, billing, and patient communication in a single browser-based application. Founded in 2004, Curve was among the early movers in cloud dental practice management and has built a platform specifically for independent dental practices and small group practices that want a modern, easy-to-use alternative to legacy on-premise systems like Dentrix and Eaglesoft. Curve's cloud architecture means there is no local server to maintain, no software to install or update, and no data backup to manage—the entire system is accessed through a web browser from any device with an internet connection.\n\nCurve's integrated imaging capability—including digital X-ray sensor compatibility, intraoral camera support, and panoramic image management—is a key differentiator in the cloud practice management market, where many competitors require a separate imaging software. By managing clinical imaging and scheduling in the same platform, Curve eliminates the need to switch between systems during patient appointments and ensures that radiographs are automatically associated with the correct patient chart and treatment records. The platform's clinical charting module supports periodontal charting, treatment planning, electronic prescriptions, and clinical notes in a unified workflow designed for the pace of a busy dental office.\n\nCurve Dental competes with Dentrix Ascend (Henry Schein's cloud offering), Eaglesoft Cloud, Carestream, and Planet DDS's Denticon in the dental practice management market. The company targets single-office practices and small groups of up to 10 locations that want cloud convenience without the enterprise complexity of DSO-focused platforms. Curve differentiates on the all-in-one nature of its platform—imaging included at no additional cost—and the simplicity of its pricing and onboarding experience for practices transitioning from legacy systems.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.